Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients

INTRODUCTION: ambrisentan and phosphodiesterase type 5 inhibitor (PDE5i) have been approved for treating patients with pulmonary arterial hypertension (PAH). Echocardiographic right ventricular pulmonary artery coupling (RVPAC) has been shown to be a valid non-invasive and alternative measurement me...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Wei-Fang, Deng, Yan, Wei, Bin, Huang, Kai, Dai, Ping, Xie, Shan-Shan, Wu, Dan-dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113403/
https://www.ncbi.nlm.nih.gov/pubmed/35592406
http://dx.doi.org/10.3389/fcvm.2022.843606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113403/
https://www.ncbi.nlm.nih.gov/pubmed/35592406
http://dx.doi.org/10.3389/fcvm.2022.843606

Ejemplares similares